Prophylactic treatment with growth hormone and insulin-like growth factor I improve systemic bacterial clearance and survival in a murine model of burn-induced gut-derived sepsis.
The purpose of this investigation was to evaluate the effects of GH and IGF-I administration in a murine model of burn-induced gut-derived sepsis. BALB/C mice were treated with 4.8 mg/kg/day of GH, 24 mg/kg/day of IGF-I or saline for 4 days. They were then administered 10(10) E. coli by gavage and subjected to 20% full thickness flame burn. All mice received allogeneic blood transfusion 5 days before burn injury to induce mild immunosuppression. Seventy-three mice were observed for survival and 51 mice were sacrificed at 4 and 20 h postburn. Blood, mesenteric lymph nodes (MLN), spleen and liver were harvested aseptically, and viable bacterial counts in the organs were determined. The small intestine was harvested for the evaluation of villus height and mitoses in the crypts. GH and IGF-I groups showed a significantly better survival than the control group. GH and IGF-I groups had significantly greater villus height and mitoses/crypt than the control group. Translocation of bacteria was not significantly different among groups, however, the relation between the numbers of viable bacteria in MLN and blood suggests that both GH and IGF-I reduced systemic spread of translocated bacteria. It is concluded that GH and IGF-I had positive effects on outcome in this model of burn-induced gut-derived sepsis. It appears that GH and IGF-I may have immune-enhancing effects and that administration of these agents may be useful for burn injury.
Fukushima
R
R
Department of Surgery II, Teikyo University School of Medicine, Tokyo, Japan.
Saito
H
H
Inoue
T
T
Fukatsu
K
K
Inaba
T
T
Han
I
I
Furukawa
S
S
Lin
M T
MT
Muto
T
T
D000818:Animals; D018988:Bacterial Translocation; D002056:Burns / Q000150:complications / Q000276:immunology / Q000382:microbiology*; D015169:Colony Count, Microbial; D004927:Escherichia coli Infections / Q000209:etiology / Q000276:immunology / Q000382:microbiology; D005260:Female; D019382:Human Growth Hormone / Q000276:immunology / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000276:immunology / Q000494:pharmacology*; D007422:Intestines / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D018805:Sepsis / Q000209:etiology / Q000276:immunology / Q000382:microbiology* / Q000401:mortality; D015996:Survival Rate
D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I